other_material
confidence high
sentiment positive
materiality 0.65
Avenue Therapeutics licenses ATX-04 from Duke University for Pompe disease; plans late-stage development
AVENUE THERAPEUTICS, INC.
- Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.
- Upfront payment plus development, regulatory, and commercial milestone payments; tiered low single-digit royalty on net sales.
- Prior Duke clinical study showed ATX-04 improved six-minute walk distance, respiratory muscle strength, and reduced glycogen.
- Avenue to assume IND and FDA orphan drug designation for Pompe disease; plans late-stage development leveraging existing data.